

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
GANEDEN BIOTECH, INC.		10/05/2012	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	SILICON VALLEY BANK
Street Address:	1550 Utica Avenue South
Internal Address:	Suite 700
City:	St. Louis Park
State/Country:	MINNESOTA
Postal Code:	55416
Entity Type:	CORPORATION: CALIFORNIA

PROPERTY NUMBERS Total: 20

Property Type	Number	Word Mark
Serial Number:	85151721	BC30
Serial Number:	85558085	SCIENCE INSPIRED BEAUTY
Serial Number:	85558082	BONICEL
Registration Number:	4130573	INTENSIVE BOWEL SUPPORT
Serial Number:	85109434	ENLIVEN
Registration Number:	3947961	
Registration Number:	3126420	DIGESTIVE ADVANTAGE
Registration Number:	3173561	ARTHRITIS ADVANTAGE
Registration Number:	3170953	DERMAL ADVANTAGE
Registration Number:	3129369	NAIL ADVANTAGE
Registration Number:	3918794	IMMUNE ADVANTAGE
Registration Number:	3794310	GANPRO
Registration Number:	3962293	GANEDEN BC30 PROBIOTIC POWERED BY DIGESTIVE & IMMUNE HEALTH

CH \$515.00 85151721

Registration Number:	3758318	THE PROLIFIC PROBIOTIC
Registration Number:	3412151	SUSTENEX
Registration Number:	3591766	GANEDENBC30
Registration Number:	2449113	CLEARLY CONFIDENT
Registration Number:	2403460	GANEDEN
Serial Number:	85003349	I.B. DEFENSE FORMULA
Serial Number:	85003270	LACTOSE DEFENSE FORMULA

CORRESPONDENCE DATA

Fax Number: 4049626571
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.
Phone: 404.885.3335
Email: ben.wiles@troutmansanders.com
Correspondent Name: BENJAMIN C. WILES
Address Line 1: TROUTMAN SANDERS LLP
Address Line 2: 600 PEACHTREE STREET NE, SUITE 5200
Address Line 4: ATLANTA, GEORGIA 30308

ATTORNEY DOCKET NUMBER:	220763.001337
NAME OF SUBMITTER:	Benjamin C. Wiles
Signature:	/Benjamin C. Wiles 63174/
Date:	10/10/2012

Total Attachments: 13

source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page1.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page2.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page3.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page4.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page5.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page6.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page7.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page8.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page9.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page10.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page11.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page12.tif
source=SVB_Ganeden (Executed Intellectual Property Security Agr 10_5_12)#page13.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of the Effective Date by and between SILICON VALLEY BANK ("**Bank**") and GANEDEN BIOTECH, INC., a Delaware corporation ("**Grantor**").

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "**Intellectual Property Collateral**"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "**Copyrights**");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and

continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

[Signature Page Follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


Address of Grantor:

5800 Landerbrook Drive
Mayfield Heights, Ohio 44124

Attn: John P. Huff

GRANTOR:

GANEDEN BIOTECH, INC.

By: 
Name: John P. Huff
Title: CFO

Address of Bank:

1550 Utica Avenue South, Suite 700
St. Louis Park, Minnesota 55416

Attn: Jay McNeil

BANK:

SILICON VALLEY BANK

By: _____
Name:
Title:

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

5800 Landerbrook Drive
Mayfield Heights, Ohio 44124

Attn: John P. Huff

GRANTOR:

GANEDEN BIOTECH, INC.

By: _____
Name:
Title:

Address of Bank:

1550 Utica Avenue South, Suite 700
St. Louis Park, Minnesota 55416

Attn: Jay McNeil

BANK:

SILICON VALLEY BANK


By: 
Name: ~~Jay McNeil~~
Title: Managing Director

EXHIBIT A

Copyrights

<u>Description</u>	Registration/ Application <u>Number</u>	Registration/ Application <u>Date</u>
None		

EXHIBIT B

Patents

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>	<u>Security Interest Issues</u>
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	8,097,247	January 17, 2012	Outstanding SI to Schiff Nutrition Group
METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	7,854,927	December 21, 2010	Outstanding SI to Schiff Nutrition Group
METHODS OF INHIBITING GROWTH OF BACTERIA, YEAST, FUNGUS, AND VIRUS WITH PSEUDOMONAS LINDBERGHII AND BACILLUS COAGULANS EXTRACELLULAR PRODUCTS	7,807,185	October 5, 2010	No
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	7,807,151	October 5, 2010	No
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	7,767,203	August 3, 2010	Outstanding SI to Schiff Nutrition Group
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	7,713,726	May 11, 2010	Outstanding SI to Schiff Nutrition Group
PROBIOTIC, LACTIC ACID- PRODUCING BACTERIA AND USES THEREOF	7,708,988	May 4, 2010	Outstanding SI to Schiff Nutrition Group
METHODS FOR INCREASING LACTOSE DIGESTION	7,700,093	April 20, 2010	Outstanding SI to Schiff Nutrition Group
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	7,544,363	June 9, 2009	No
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	7,541,042	June 2, 2009	No
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	7,507,402	March 24, 2009	No
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS	7,374,753	May 20, 2008	Outstanding SI to Schiff Nutrition

Active 8652639v1 220763.001337

TRADEMARK
REEL: 004878 FRAME: 0155

ASSOCIATED WITH SIDS			Group
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	7,371,407	May 13, 2008	No
METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS	7,232,571	June 19, 2007	Outstanding SI to Schiff Nutrition Group
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	7,048,950	May 23, 2006	No
ABSORBENT PRODUCT CONTAINING ABSORBENT STRUCTURE AND BACILLUS COAGULANS	7,025,974	April 11, 2006	No
TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACILLUS BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	6,905,692	June 14, 2005	No
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	6,849,256	February 1, 2005	Outstanding SI to Schiff Nutrition Group
METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS	6,811,786	November 2, 2004	Outstanding SI to Schiff Nutrition Group
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS & PREPARATIONS	6,733,751	May 11, 2004	No
TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACILLUS BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	6,723,326	April 20, 2004	Outstanding SI to Schiff Nutrition Group
ABSORBENT PRODUCT CONTAINING ABSORBENT STRUCTURE AND BACILLUS COAGULANS	6,716,435	April 6, 2004	No
TOPICAL COMPOSITIONS CONTAINING EXTRACELLULAR PRODUCTS OF PSEUDOMONAS LINDBERGHII AND EMU OIL	6,645,506	November 11, 2003	No
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS AND PREPARATIONS	6,531,126	March 11, 2003	No
PROBIOTIC, LACTIC ACID-	6,461,607	October 8, 2002	Outstanding SI to

PRODUCING BACTERIA AND USES THEREOF			Schiff Nutrition Group
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	20110189145 12/756658	April 8, 2010	Outstanding SI to Schiff Nutrition Group
METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	20110064708 12/951859	November 22, 2010	Outstanding SI to Schiff Nutrition Group
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	20110020305 12/897590	October 4, 2010	No
PROBIOTIC CONFECTION AND LIPID COMPOSITIONS	20110256216 13/086675	April 14, 2011	No
BEVERAGE COMPOSITIONS	20110195154 13/087803	April 15, 2011	Outstanding SI to Schiff Nutrition Group
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	20110020306 12/897604	October 4, 2010	Outstanding SI to Schiff Nutrition Group
INACTIVATED BACTERIAL CELL FORMULATION	20100297092 12/770457	April 29, 2010	Outstanding SI to Schiff Nutrition Group
PROBIOTIC GRAIN-BASED COMPOSITIONS	20100210000 12/580622	October 16, 2009	Outstanding SI to Schiff Nutrition Group
COMPOSITIONS AND METHODS FOR CLEANING SURFACES	20090305387 12/363442	January 30, 2009	No
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20090238907 12/479064	September 24, 2009	No
COMPOSITIONS AND METHODS FOR ENHANCING PAPER PRODUCT DEGRADATION	20090191609 12/229842	August 27, 2008	No
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	20090186057 12/370255	February 12, 2009	No
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20090181000 12/365798	February 4, 2009	Outstanding SI to Schiff Nutrition Group
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20090142315 12/365808	February 4, 2009	Outstanding SI to Schiff Nutrition Group
BAKED GOODS	20090186126 12/229862	August 27, 2008	Outstanding SI to Schiff Nutrition

			Group
BEVERAGE COMPOSITIONS	20090232941 12/253048	October 16, 2008	Outstanding SI to Schiff Nutrition Group
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	20080112942 11/985617	November 15, 2007	Outstanding SI to Schiff Nutrition Group
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20080089963 11/974427	October 12, 2007	No
TOPICAL COMPOSITIONS CONTAINING BACILLUS COAGULANS EXTRACELLULAR PRODUCTS AND USES THEREOF	20050271758 11/152894	June 14, 2005	No
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS	20080193429 12/148200	April 17, 2008	Outstanding SI to Schiff Nutrition Group
USE OF EMU OIL AND ITS VARIOUS FRACTIONS AS A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS & PREPARATIONS	20080274153 12/080402	April 1, 2008	No
INHIBITION OF PATHOGENS BY PROBIOTIC BACTERIA	20050232909 11/005897	December 6, 2004	Outstanding SI to Schiff Nutrition Group
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	20030031659 10/264745	October 4, 2002	Outstanding SI to Schiff Nutrition Group
PROBIOTIC COMPOSITIONS	20030124104 10/287904	November 5, 2002	No
PROBIOTIC CONFECTION AND LIPID COMPOSITIONS	PCT/US2011/032449	April 14, 2011	N/A
INACTIVATED BACTERIAL CELL FORMULATION	PCT/US2010/032993	April 29, 2010	N/A
PROBIOTIC GRAIN-BASED COMPOSITIONS	PCT/US2009/060983	October 16, 2009	N/A
COMPOSITIONS AND METHODS FOR CLEANING SURFACES	PCT/US2009/000608	January 30, 2009	N/A
BEVERAGE COMPOSITIONS	PCT/US2008/011812	October 16, 2008	N/A
COMPOSITIONS AND METHODS FOR ENHANCING PAPER PRODUCT DEGRADATION	PCT/US2008/010141	August 27, 2008	N/A
BAKED GOODS	PCT/US2008/010143	August 27, 2008	N/A

METHODS AND COMPOSITIONS FOR THE DIETARY MANAGEMENT OF AUTOIMMUNE DISORDERS	PCT/US2005/016469	May 11, 2005	N/A
INHIBITION OF PATHOGENS BY BACILLUS COAGULANS STRAINS	PCT/US2000/030737	November 8, 2000	N/A
USE OF EMU OIL A CARRIER FOR ANTIFUNGAL, ANTIBACTERIAL, AND ANTIVIRAL MEDICATIONS	PCT/US2000/023448	August 25, 2000	N/A
IMPROVED TOPICAL COMPOSITIONS CONTAINING PROBIOTIC BACTERIA, SPORES, AND EXTRACELLULAR PRODUCTS AND USES THEREOF	PCT/US2000/023300	August 25, 2000	N/A
METHODS FOR INHIBITING MICROBIAL INFECTIONS ASSOCIATED WITH SANITARY PRODUCTS	PCT/US2000/010222	April 14, 2000	N/A
PROBIOTIC, LACTIC ACID-PRODUCING BACTERIA AND USES THEREOF	PCT/US1999/017862	August 6, 1999	N/A
METHODS FOR INCREASING THE SOLUBILITY OF NUTRITIONAL MATERIALS USING PROBIOTIC LACTIC ACID-PRODUCING BACTERIA	PCT/US1999/017671	August 6, 1999	N/A
METHODS FOR REDUCING CHOLESTEROL USING \$(BACILLUS COAGULANS) SPORES, SYSTEMS AND COMPOSITIONS	PCT/US1999/007360	April 1, 1999	N/A
PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS	PCT/US1998/011347	June 3, 1998	N/A
TOPICAL USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS	PCT/US1998/007307	April 10, 1998	N/A
METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION	PCT/US2004/040513	December 3, 2004	N/A

EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>	<u>Security Interest Issues</u>
BC30	85/151721	October 13, 2010	Outstanding SI to Schiff Nutrition
SCIENCE INSPIRED BEAUTY	85/558085	March 1, 2012	No
BONICEL	85/558082	March 1, 2012	No
INTENSIVE BOWEL SUPPORT	4,130,573	April 24, 2012	No
ENLIVEN	85/109434	August 17, 2010	No
DESIGN ONLY	3,947,961	April 19, 2011	No
DIGESTIVE ADVANTAGE	3,126,420	August 8, 2006	Outstanding SI to Schiff Nutrition & Airborne, Inc
ARTHRITIS ADVANTAGE	3,173,561	November 21, 2006	Outstanding SI to Schiff Nutrition & Airborne, Inc
DERMAL ADVANTAGE	3,170,953	November 14, 2006	Outstanding SI to Schiff Nutrition & Airborne, Inc.
NAIL ADVANTAGE	3,129,369	August 15, 2006	No
IMMUNE ADVANTAGE	3,918,794	February 15, 2011	Outstanding SI to Schiff Nutrition & Airborne, Inc.
GANPRO	3,794,310	May 25, 2010	No
GANEDEN BC30 PROBIOTIC POWERED BY DIGESTIVE & IMMUNE HEALTH	3,962,293	May 17, 2011	Outstanding SI to Schiff Nutrition
THE PROLIFIC PROBIOTIC	3,758,318	March 9, 2010	Outstanding SI to Schiff Nutrition & Airborne, Inc.
SUSTENEX	3,412,151	April 15, 2008	Outstanding SI to Schiff Nutrition & Airborne, Inc.
GANEDENBC30	3,591,766	March 17, 2009	Outstanding SI to Schiff Nutrition
CLEARLY CONFIDENT	2,449,113	May 8, 2001	No
GANEDEN	2,403,460	November 14, 2000	No

I.B. DEFENSE FORMULA	85/003349	March 31, 2010	No
LACTOSE DEFENSE FORMULA	85/003270	March 31, 2010	No
GANEDEN BC 30	CA156968200	March 14, 2012	N/A
GANEDEN BC 30 CULTURES DESIGN	CA154547600	September 22, 2011	N/A
ENLIVEN	CA151615600	February 17, 2011	N/A
LACTOSE DEFENSE FORMULA	CA149996000	September 30, 2010	N/A
GANEDEN BC30 PROBIOTIC POWERED BY DIGESTIVE & IMMUNE HEALTH	CA144904700	August 14, 2009	N/A
THE PROLIFIC PROBIOTIC	CA141563700	October 23, 2008	N/A
DIGESTIVE ADVANTAGE	CA135049300	June 6, 2007	N/A
GANEDENBC30 DESIGN	CA134471200	April 24, 2007	N/A
SUSTENEX	CA134452000	April 23, 2007	N/A
GANEDEN BC 30 CULTURES	EC010114106	July 11, 2011	N/A
ENLIVEN	EC009948324	May 6, 2011	N/A
LACTOSE DEFENSE FORMULA	EC009413121	September 30, 2010	N/A
I.B. DEFENSE FORMULA	EC009413171	September 30, 2010	N/A
THE PROLIFIC PROBIOTIC	EC007338064	October 23, 2008	N/A
DIGESTIVE ADVANTAGE	EC005953104	May 30, 2007	N/A
GANEDENBC30	EC005850797	April 23, 2007	N/A
SUSTENEX	EC005850086	April 23, 2007	N/A
ENLIVEN	WO01069997	February 17, 2011	N/A

EXHIBIT D

Mask Works

<u>Description</u>	Registration/ Application <u>Number</u>	Registration/ Application <u>Date</u>
None		